Unlock instant, AI-driven research and patent intelligence for your innovation.

Combination methods of inhibiting tumor growth with vascular endothelial growth factor receptor antagonist

A growth factor receptor and epidermal growth factor technology, applied in the field of combined therapy to inhibit tumor growth with vascular endothelial growth factor receptor antagonists, can solve the problem of low expression levels of VEGF ligands and their receptors

Inactive Publication Date: 2009-02-04
IMCLONE SYSTEMS
View PDF55 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Although VEGF ligands are upregulated in tumor cells and their receptors are also upregulated in tumor-infiltrating vascular endothelial cells, VEGF ligands and their receptors are expressed at low levels in normal cells not associated with angiogenesis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination methods of inhibiting tumor growth with vascular endothelial growth factor receptor antagonist
  • Combination methods of inhibiting tumor growth with vascular endothelial growth factor receptor antagonist
  • Combination methods of inhibiting tumor growth with vascular endothelial growth factor receptor antagonist

Examples

Experimental program
Comparison scheme
Effect test

Embodiment VIII

[0037] The VEGF receptor antagonist is before, during, or after starting chemotherapy or radiotherapy, and any combination thereof, i.e., before and during, before and after, during and after, or before starting chemotherapy and / or radiotherapy, During, and after giving. For example, when the VEGF receptor antagonist is an antibody, the antibody is usually administered between 1-30 days, preferably 3-20 days, more preferably 5-12 days before the start of radiotherapy and / or chemotherapy.

[0038] radiotherapy

[0039] The radiation source used in conjunction with the VEGF receptor antagonist may be extrinsic or intrinsic to the patient being treated. When the radiation source is external to the patient, the therapy is called external beam radiation therapy (EBRT). When the source of radiation is internal to the patient, the therapy is called brachytherapy (BT).

[0040] Radiation therapy is administered according to well-known standard techniques, using standard equipment m...

Embodiment 1

[0180] Example 1. Cell lines and media

[0181] NIH 3T3 cells were obtained from the American Type Culture Collection (Rockville MD). The C441 cell line was constructed by transfecting 3T3 cells with chimeric receptor mouse flk-1(VEGFR-2) / human fms. 10A2, a 3T3 transfectant containing the chimeric receptor human fms / mouse FLK-2, has been isolated and characterized (Dosil et al., Mol. Cell. Biol. 13:6572-6585 (1993)). Cells were usually maintained in Dulbecco's modified Eagle's medium (DME) supplemented with 10% calf serum (CS), 1 mM L-glutamine, antibiotics, and 600 μg / ml G418 (Geneticin; Sigma, St Louis MO).

[0182] The glioblastoma cell line, GBM-18, was maintained in DME supplemented with 5% calf serum, 1 mM L-glutamine, and antibiotics.

[0183] A stable 3T3 line secreting a soluble chimeric protein, mouse flk-1(VEGFR-2):SEAPs (secreted alkaline phosphatases) was produced and maintained in DMEM and 10% calf serum. Conditioned medium was collected. Isolation of soluble...

Embodiment II

[0184] Example II. Isolation of Monoclonal Antibodies

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a method of reducing or inhibiting tumor growth in a mammal, comprising treating the mammal with a therapeutically effective amount of a VEGF receptor antagonist in combination with radiotherapy, chemotherapy, and / or other receptor antagonists.

Description

[0001] This application is a continuation-in-part of application No. 09 / 798,689 filed March 2, 2001, which is a pending application No. 09 / 401,163 filed September 22, 1999 Continuation, Application No. 09 / 401,163 is a continuation-in-part of Application No. 08 / 967,113, filed November 10, 1997, Application No. 08 / 967,113 is a part of Patent No. 5,861,499, filed September 3, 1996 Continuation, Patent No. 5,861,499 is a continuation-in-part of Application No. 08 / 476,533 filed June 7, 1995, Application No. 08 / 476,533 is a continuation-in-part of Patent No. 5,840,301 filed October 20, 1994 , Patent No. 5,840,301 is an abandoned, continuation-in-part application No. 08 / 196,041 filed on February 10, 1994. The entire contents of the aforementioned prior application are hereby incorporated by reference. field of invention [0002] The present invention relates to methods of treating tumors utilizing vascular endothelial growth factor (VEGF) receptor antagonists in combination with che...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/395A61P35/00A61K51/00
Inventor 帕特里夏·罗克韦尔尼尔 I·戈尔茨坦
Owner IMCLONE SYSTEMS